Share Name Share Symbol Market Type Share ISIN Share Description
Horizon Discvry LSE:HZD London Ordinary Share GB00BK8FL363 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00p -0.85% 232.00p 231.00p 233.00p - - - 28,387 10:37:36
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 24.1 -12.5 -12.1 - 345.88

Horizon Discvry Share Discussion Threads

Showing 876 to 899 of 900 messages
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
DateSubjectAuthorDiscuss
15/1/2018
17:05
Interesting couple of days trading. HZD has been rather quiet on the RNS front in terms of partnership / product developments - maybe something exciting is brewing :)
mamcw
12/1/2018
13:07
and this morning I suspect we have the answer. 2 large trades of 225K each followed by a price rebound. suspect these were large sales that had dragged the share price down - and presents a buying opportunity.
melody9999
08/1/2018
11:51
may - I agree and am perplexed too. Strong update from ABC recently with similar model. Just seems to be drifting on a small number of sells.
melody9999
02/1/2018
21:14
Anybody got any clues as to the downward movement today? All the news via linkedIn etc seems reasonably positive.
mayflyniall
19/12/2017
12:40
Horizon Discovery enters into agreement with Roche Diagnostics to support the development of immunohistochemistry assays for oncology · Horizon to develop and manufacture FFPE Reference Standards that express NTRK fusion biomarkers · Standards to be derived from custom gene edited cell lines · Agreement builds upon Horizon's pre-existing partnership with Roche Diagnostics Cambridge, UK, 18 December, 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Company"), a global leader in gene editing and gene modulation technologies, today announces that it has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays. Under the terms of the agreement, Horizon will develop and provide Reference Standard material expressing neurotrophic tropomyosin receptor kinase (NTRK) fusion biomarkers. NTRK gene rearrangements have recently emerged as promising targets for cancer therapy, and a number of novel compounds have been developed against the fusion proteins that arise from these molecular alterations. Their effective application, however, depends upon the accurate determination of the genotype of patients, which is primarily carried out through IHC-based diagnostic testing. Horizon's Reference Standards will be derived from cell lines generated using the Company's industry-leading gene editing platform to include knock-ins (KI) of NTRK 1,2 and 3 fusion cDNA (each under the control of multiple promoters), to achieve low to high levels of protein expression in selected cell lines. The cells will be supplied in FFPE (formalin-fixed paraffin embedded) format, thereby mimicking real patient samples for better control of variability across the complete diagnostic workflow. The project is expected to be completed within 12 months. This agreement builds on the Horizon-Roche partnership announced in September 2016, which comprised the development, manufacture and commercialisation of cell line derivative materials for use as IHC Reference Standards in cancer tissue diagnostics, to support the development and validation of IHC assays. Dr. Darrin M Disley, Chief Executive Officer, Horizon Discovery Group, commented: "Horizon continues to establish itself as a leading supporter of the development and validation of molecular diagnostics by providing reliable and high quality reference standards to assay developers. We are very pleased to announce this agreement, further strengthening our ongoing partnership with Roche, and we look forward to continuing to work alongside them as they develop additional important diagnostic assays in areas of significant need."
mamcw
07/12/2017
13:48
Interesting the price takes a dip today when the product it licenses is getting big coverage: hxxp://www.telegraph.co.uk/science/2017/12/05/genetically-mutated-rats-could-released-britain-solve-rodent/ Also a little on FT Alphaville
argylerich
16/11/2017
12:17
whats causing this to get whacked today??
pjj71
27/9/2017
10:26
why does this stock get whacked every day at around the same time? Is some algo robot switched on?
pjj71
26/9/2017
09:02
Results well trailed to the market. Rate of margin expansion is much better than previously forecast, with more to come as management continue to focus on cost control. But I suspect it will be 6-12 months before it becomes clear whether HZD has done the transformational deal that management claims.
mamcw
12/9/2017
12:08
Agreed. I'll buy (again) below 200.
small crow
12/9/2017
11:17
No profit and no divi looks a bit expensive at the mo. Setting the foundation for the future. I guess a buy soon
mj19
11/9/2017
07:09
So they don't make any profit yet?
mj19
08/9/2017
11:59
A comforting trading update today: all going as expected. Full year EBITDA for the enlarged group is expected to be approximately break-even prior to exceptional items relating to the acquisition, integration and restructuring costs and discontinued operations..
gnnmartin
04/9/2017
08:25
Might test 210
mj19
01/9/2017
09:28
I'm out. On the watch list to maybe buy again later.
grabster
30/8/2017
08:17
having top sliced nearer 300p, I have topped up again today. onwards and upwards from here.
melody9999
08/8/2017
18:57
Congrats to those brave souls who piled in a few months ago when the share price was dropping like a stone
kestelmill
08/8/2017
17:10
Impressive indeed and I bet more to come.
mirabeau
08/8/2017
13:55
Also more than double the January 1st price of £1.43 -Happy days! Sold one third on the last spike expecting a drop but will be happy if this continues.
cumbrian2
08/8/2017
13:30
Blimey, 40% above the placing price. Gotta admit - I didnt expect this reaction...
phowdo
08/8/2017
13:21
Happy days. If ever there was a case of run your winners, cut your losers, this is it.
mamcw
07/8/2017
09:17
An anecdote - post completion of the Dharmacon deal, HZD will in the top 50 of AIM stocks by market capitalisation. AIM stocks are increasingly being used by wealth planners for the rich as an IHT shelter, particularly by those fearful of a Corbyn government.
mamcw
03/8/2017
10:36
Some determined buying this morning - looks like we could be about to re-test the highs
mamcw
27/7/2017
10:09
HZD make an EBITDA loss but this should turn to profit once Dharmacon is bolted on (thanks to Dharmacon profit)
kestelmill
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20180119 11:50:10